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Background: The exact molecular mechanisms regarding HTLV-1 Tax-mediated viral gene expression and CD4
T-cell transformation have yet to be fully delineated. Herein, utilizing virus-infected primary CD4+ T cells and the
virus-producing cell line, MT-2, we describe the involvement and regulation of Myocyte enhancer factor-2 (specifically
MEF-2A) during the course of HTLV-1 infection and associated disease syndrome.
Results: Inhibition of MEF-2 expression by shRNA and its activity by HDAC9 led to reduced viral replication and T-cell
transformation in correlation with a heightened expression of MEF-2 in ATL patients. Mechanistically, MEF-2 was recruited
to the viral promoter (LTR, long terminal repeat) in the context of chromatin, and constituted Tax/CREB transcriptional
complex via direct binding to the HTLV-1 LTR. Furthermore, an increase in MEF-2 expression was observed upon
infection in an extent similar to CREB (known Tax-interacting transcription factor), and HATs (p300, CBP, and
p/CAF). Confocal imaging confirmed MEF-2 co-localization with Tax and these proteins were also shown to
interact by co-immunoprecipitation. MEF-2 stabilization of Tax/CREB complex was confirmed by a novel
promoter-binding assay that highlighted the involvement of NFAT (nuclear factor of activated T cells) in this
process via Tax-mediated activation of calcineurin (a calcium-dependent serine-threonine phosphatase). MEF-2-
integrated signaling pathways (PI3K/Akt, NF-κB, MAPK, JAK/STAT, and TGF-β) were also activated during HTLV-1
infection of primary CD4+ T cells, possibly regulating MEF-2 activity.
Conclusions: We demonstrate the involvement of MEF-2 in Tax-mediated LTR activation, viral replication, and
T-cell transformation in correlation with its heightened expression in ATL patients through direct binding to DNA
within the HTLV-1 LTR.
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HTLV-1 is the etiologic agent of adult T cell leukemia
(ATL), a progressive lymphoma, and HTLV-1 associated
myelopathy/tropical spastic paraparesis (HAM/TSP) [1-6].
Globally, as many as 20 million people are infected with
HTLV-1 [7], yet most remain asymptomatic carriers [8-10].
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unless otherwise stated.1 into a quiescent versus active replication mode are not
clearly understood; however, it is well established that ex-
pression of the viral transactivator protein, Tax, is required
for the efficient viral gene expression [11-13].
Upon entering its target cell (CD4+ T cells, primarily
CD4+CD25+ cells), HTLV-1 ssRNA(+) is reverse tran-
scribed and integrated semirandomly into the host gen-
ome as a provirus [14]. Proviral gene expression depends
on Tax [11-13,15,16] and specific cellular transcription
factors (TFs) during both primary infection and viral re-
activation from latency [17,18]. Tax is a 40 kDa proteinis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cific TFs and coactivators that facilitate its binding to
Tax-responsive elements (TRE) on the long terminal re-
peat (LTR) [19-21]. cAMP response element homolo-
gous sequences within TRE provide CRE-binding
protein (CREB) docking sites where Tax interacts with
the CREB homodimer on the viral LTR [22-24]. Tax/
CREB binding to the viral promoter initiates the recruit-
ment of histone acetyl transferases (HATs) including
p300, p300/CREB-binding protein (CBP), and p300/CBP
associated factor (p/CAF) [25-28], which enables nucleo-
some disassembly and transcriptional activation [29-32].
The role of TFs other than CREB needs to be delineated
in HTLV-1 promoter activation and gene expression.
Here, we present investigations on Tax-mediated LTR
activation in the context of viral infection using HTLV-
infected primary CD4+ T cells and the virus-producing
T cell line (MT-2) and describe the involvement of myo-
cyte enhancer factor-2 (MEF-2) in this process.
MEF-2 was originally described as a transcriptional
regulator in cardiac and skeletal muscle [33-35]. In
mammals, there are four MEF-2 genes that give rise to
MEF-2A, MEF-2B, MEF-2C, and MEF-2D. At the N-
terminus, four isotypes are highly conserved and contain
a MADS (MCM1, Agamous, Deficiens and serum re-
sponse factor) domain whereas the highly variable C-
termini contain transcription activation domains (TADs),
which recruit coactivators, histone modification enzymes
and factors associated with nucleosome disassembly and
remodeling to activate gene expression [33-35]. All MEF-2
isoforms exhibit significant amino acid sequence similarity
within their DNA binding domain [36]. MEF-2 is
expressed at high levels in neurons and lymphocytes,
where it serves as a regulator of neuronal and immune cell
differentiation and function [37,38]. MEF-2A expression is
quite ubiquitous unlike MEF-2C and -2B, which remain
somewhat tissue tropic, and MEF-2D is a comparatively
weak transcriptional activator [39]. The studies presented
herein primarily refer to MEF-2A since most of available
reagents (antibodies, plasmids, etc.) are specific to this iso-
form of MEF-2. It is also true for the majority of published
work on this cellular factor.
MEF-2 is necessary for the transcriptional activation of
Interleukin 2 (IL-2) during peripheral T cell activation
[40]. It plays a crucial role in T-lymphocyte apoptosis by
regulating expression of Nuclear receptor subfamily 4,
group A, member 1 (NUR77) [41,42]. Within T lympho-
cytes, MEF-2 activity is subjected to complex levels of
regulation. MEF-2 associates with a variety of regulating
proteins: p300, p/CAF, Nuclear factor of activated T-
cells, cytoplasmic, calcineurin-dependent 2 (NFATC2),
Nuclear receptor coactivator 2 (NCOA2), Myogenic differ-
entiation 1 (MYOD), Mitogen-activated protein kinase 7
(MAPK7), Calcineurin binding protein 1 (CABIN1), ClassII histone deacetylases (HDAC4, HDAC5, HDAC7,
HDAC9) [41,43] and is regulated by MAP kinase cascades
and calcium signaling.
Association of Class II histone deacetylases such as
HDAC9 results in deacetylation of nucleosomal histones
surrounding MEF-2 DNA-binding sites, with subsequent
suppression of MEF-2-dependent genes [38]. MAPKs
couple MEF-2 to multiple signaling pathways for cell
growth and differentiation [44-47]. MAPK14 and MAPK11
phosphorylate and activate MEF-2A and MEF-2C, and
MAPK7 is capable of phosphorylating and activating
MEF-2A, MEF-2C and MEF-2D [48,49]. MAPK7 and
Extracellular signal-regulated kinase 5 (ERK5), itself are
phosphorylated and activated by MEKK2 and 3 [50]. In
response to MAPK7, MAPK11 and MAPK14, MEF-2
activates the transcription factor Jun oncogene (c-Jun),
which participates in regulation of proliferation
[38,51,52]. Interestingly, MAP kinases are associated
with HTLV-1 pathogenesis [53], and Tax protein has
been shown to activate p38 [54]. Since both p38 and
ERK5 activate MEF-2 by phosphorylation [44,49,55-60],
it is highly likely that activation of these signaling path-
ways by Tax activate MEF-2. Therefore, we sought to
determine if MEF-2 participates in Tax-mediated trans-
activation of HTLV-1 promoter.
Not much is known about the role of MEF-2 in viral
pathogenesis except for the Epstein-Barr virus (EBV) in-
fection. EBV latency has been linked with chromatin re-
modeling through the recruitment of MEF-2 to the viral
promoter [61-63]. Here, utilizing HTLV-infected primary
CD4 T cells, we provide the first evidence for the in-
volvement of MEF-2 in Tax-mediated LTR activation,
viral replication, and T-cell transformation in correlation
with its heightened expression in ATL patients. MEF-2
was also shown to directly bind to DNA within the
HTLV-1 LTR to an imperfect site. Molecular mecha-
nisms involved activation and recruitment of MEF-2 on
the LTR in the context of chromatin and co-regulation
of transcriptional complex involving both Tax and
CREB.
Results
MEF-2 inhibition reduces Tax-mediated LTR
trans-activation, and viral replication
In order to understand effects of MEF-2 on transcrip-
tional activation of HTLV-1 LTR, we transfected Jurkat
cells with pU3R-luc (HTLV-1 5′ LTR luciferase reporter
vector), and plasmids expressing Tax (pCMV-Tax),
MEF-2A (p3X-Luc-MEF-2), and HDAC9 (pHDAC9).
Also, the pLKO.1-puro shMEF-2A plasmid was used to
knock down MEF-2A expression. As expected, LTR ac-
tivity significantly increased in the presence of Tax
(Figure 1A) Overexpression of MEF-2A, in the absence
of Tax did not have any impact on LTR activation but
Figure 1 (See legend on next page.)
Jain et al. Retrovirology  (2015) 12:23 Page 3 of 24
(See figure on previous page.)
Figure 1 MEF-2 inhibition reduces HTLV-1 LTR transactivation, Tax expression, and viral replication. (A) Transient transfection of Jurkat
cells with pU3R-luc (HTLV-1 LTR luciferase reporter construct) as well as plasmids that express Tax, MEF-2A, HDAC9 and MEF-2A shRNA, was done
as described in Methods. Before co-transfecting two or more plasmids, each of these plasmids was transfected alone to establish the background
levels of luciferase activity. Cells were collected 24 hr post-transfection, lysed and assayed using the dual luciferase assay system. Firefly luciferase
activity was normalized with that of Renilla luciferase expressed from phRL/CMV. Each bar represents the average of triplicate samples. Significance
among groups was derived by student’s t-test to determine the p-value. (*p < 0.05). (B) MT-2 cells were transfected with either scrambled or shMEF-2
plasmid. Western blot analysis was performed at 24 hr and 48 hr to determine protein levels of MEF-2, Tax, and beta-actin. Data represent one of two
separate experiments. (C) To analyze effects of shMEF-2A on virus production, transfected MT-2 cells were washed at 48 hr and incubated in fresh
medium for another 24–36 hr. Thereafter, supernatants were assessed for HTLV-1 core protein levels (pg/ml) by the p19-specific ELISA (ZeptoMetrix,
Buffalo, NY). (D) MT-2 cells were transfected either with a mock plasmid or MITR/HDAC9 plasmids followed by cell collection at every 24 hr over a
72 hr period. Real-time PCR analyses were performed to determine relative mRNA levels of Tax and p19. Data is representative of at least three
independent experiments.
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value of 0.1. On the other hand, inhibition of MEF-2A
expression by shRNA or its activity by HDAC9 demon-
strated significant reduction in Tax-mediated LTR acti-
vation (Figure 1A), suggesting that Tax partners with
cellular MEF-2 during the transactivation process. Each
plasmid was titrated at various concentrations and was
used at an optimal dose. Transfection efficiency was
measured using a pMX-GFP plasmid (Lonza) and
ranged from 58-64% in triplicate samples (Additional
file 1: Figure S1A). Besides Tax plasmid no other plas-
mid has any direct effect on LTR activation providing
internal control to the assay and avoiding the possibil-
ity of a general suppression with shMEF-2A and/or
pHDAC9. For other controls, scrambled shRNA was
used, MEF-2 inhibition was confirmed by end-point
RT-PCR (Additional file 1: Figure S1B), and LDH cyto-
toxicity assay was performed to measure extracellular
LDH in transfection media to confirm comparable via-
bility of transfected cells among experimental variables
(Additional file 1: Figure S1C).
Since the utilized dose of Tax plasmid exhibited lim-
ited LTR transactivation in Jurkat cells, we repeated
some of the key observations in 293 T cells and observed
an enhanced Tax activity, which was significantly re-
duced in the presence of both shMEF-2A and HDAC9
plasmids but not MEF-2A plasmid (Additional file 1:
Figure S1D) in line with data obtained with Jurkat cells.
As expected, MEF-2A knockdown alone in the absence
of Tax had no effect on LTR activity avoiding the possi-
bility of a general suppression.
Impact of MEF-2A shRNA and HDAC9 was further
assessed in the setting of ongoing viral replication in
MT-2 cells. First with an shRNA approach, we observed
a reduction in Tax protein expression concurrent with
decrease in MEF-2A expression upon shRNA adminis-
tration into MT-2 cells (Figure 1B). This was also con-
firmed by FACS (data not shown) and translated at the
level of virus production by MT-2 cells; wherein shMEF-
2 demonstrated a significant (p < 0.001) reduction in p19
levels (Figure 1C). Next, upon HDAC9 overexpression(confirmed by Western blotting) in MT-2 cells, we noted
a significant reduction in both Tax and p19 viral tran-
scripts (Figure 1D). Tax downregulation was stable over
a 72 hr period, with approximately 5-log down-
regulation at 24 hr, 4.5-log at 48 hr, and 3-log downregu-
lation at 72 hr. Importantly, we also observed p19
mRNA downregulation of approximately 4-log at 24 hr,
3.5-log at 48 hr, and 2.5-log at 72 hr with HDAC9 over-
expression, confirming MEF-2 involvement in HTLV-1
LTR activation, subsequent Tax expression and viral rep-
lication as well as productive infection.
MEF-2A is essential for HTLV-1-mediated T-cell
proliferation
In order to investigate whether MEF-2A is required for
HTLV-1-induced transformation of T cells, we used a
well-established co-culture model wherein HTLV-1 im-
mortalizes primary T lymphocytes [64]. PBMCs were
transduced with lentivirus expressing control scrambled
or ShMEF-2A and subjected to a co-culture assay with
MT-2 cells as the source of virus. Transduced cells
were selected with puromycin after 3 weeks. As seen in
Figure 2A, PBMCs transduced with shMEF-2A ceased
proliferating at about 3 weeks whereas PBMCs express-
ing control shRNA continued cell growth and became
immortalized. Control untransduced PBMCs were rap-
idly killed upon adding puromycin (Figure 2A). As ex-
pected, PBMCs by themselves without MT-2 did not
survive long enough, thus it is difficult to determine
from this assay whether MEF-2 is required for survival
of cells in the absence of HTLV-1. Therefore, to further
investigate this phenomenon, we determined changes
in the cell cycle of Jurkat and MT-2 cells in the pres-
ence or absence of MEF-2 (shMEF-2A) by the PI-based
assessment of DNA content in G0/G1, S, and G2/M
phase. Early steps in cell death are characterized by
internucleosomal DNA fragmentation and chromatin
condensation, thus the apoptotic stage sub-G1 was also
deduced. Figure 2B (left panel) displays a dramatic de-
crease of G0/G1 (13%) phase in shMEF-2A-transfected
MT-2 cells compared to control- (56%) or mock
Figure 2 (See legend on next page.)
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Figure 2 MEF-2 inhibition perturbs HTLV-1-mediated T-cell transformation in correlation with a heightened MEF-2 expression in ATL
patients. (A) PBMCs were transduced with scrambled or shMEF-2 expressing lentivirus by spinoculation. Viable cell proliferation of PBMCs was
determined by trypan blue exclusion assay, after co-culture with lethally irradiated MT-2 cells for the indicated times. Error bars represent standard
deviation of triplicate samples with high significance (***p < 0.001) between shMEF-2 versus shControl samples. (B) MT-2 and Jurkat cells were
collected at 24 hr post a 3-day transfection followed by staining with propidium iodide (PI-25 μg/ml, RNAase- 40 μg/ml, sodium citrate-0.1% and
Triton-100 × −0.03%). Cell cycle progression of MT-2 and Jurkat cells were observed via flow cytometry with no transfection (upper panel), mock
transfected (middle panel) and shMEF2 plasmid (2.5 μg/1×106 cells) transfection (lower panel). The percentage of sub-G1 cells, G0/G1, S and
G2-M cells was analyzed using the FLowjo software. (C) MEF-2A mRNA levels was determined by the quantitative real-time PCR as described in
Methods. At least two replicates per donor were processed and MEF-2 levels were compared between seronegative controls and ATL patients
(n = 3, each). Each point represents average mRNA expression in individual donors. Bars represent mean with Standard Error (SEM) derived by a
two-tailed, unpaired nonparametric t-test (Mann–Whitney).
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the G2/M and M phases also decreased from 12% to
5% and those of S phase decreased from 12% to 9% in
mock versus shMEF-2A conditions, respectively. This
population reduction was concomitant with the emer-
gence of a characteristic hypodiploid (<2 N DNA) sub-
G1 peak, which indicates apoptotic cells. shMEF-2A
containing cells showed a dramatic increase in the sub-
G1 peak with 73% cells showing signs of undergoing
apoptosis compared to 28% in the mock-transfected
cells. Interestingly, this phenomenon of increased sub-
G1 events was not observed in Jurkat cells (Figure 2B,
right panel). For Jurkat, control, mock or shMEF-2A
samples showed fairly similar percentages of cells in
the G0/G1, S and G2/M phases. This data suggest that
observed MEF-2 effects are specific to HTLV-1 and
more so to Tax since lack of MEF-2A reduces LTR trans-
activation and subsequent Tax expression (Figure 1), con-
sequently leading to cell cycle arrest and dispensing MT-2
cells of G0/G1 and G2/M phases to apoptosis.
The immortalization of primary T cells is a pathologic
hallmark of ATL, and our data thus far suggested in-
volvement of MEF-2A in this process. Interestingly, we
observed a 7-fold increase in relative mRNA levels of
MEF-2A in ATL patients as compared to seronegative
control (Figure 2C) with a p-value of <0.18 in a two-
tailed, unpaired nonparametric t-test (Mann–Whitney).
Similar results were obtained while comparing MEF-2A
levels in ATL patients with silent carriers of virus estab-
lishing clinical relevance of this cellular factor in HTLV-
1-associated disease pathologies. A heightened MEF-2A
expression in ATL patients could suggest a direct role of
MEF-2A in the genesis and/or maintenance of T-cell
leukemia in these patients.
MEF-2A is recruited to the HTLV-1 LTR in the context of
chromatin
Having generated confidence in MEF-2 involvement in
HTLV-1 pathogenesis, we proceeded to understand the
underlying molecular interactions in the context of pri-
mary CD4+ T cells and viral infection. We infected pri-
mary CD4+ T cells with HTLV-1 as previouslydescribed [65,66], and confirmed intracellular Tax ex-
pression by flow cytometry as well as by Western blot-
ting (Additional file 2: Figure S2). Upon confirmation
of infection, cells were subjected to ChIP analyses. In
both cell lines and primary cells, we noted strong bind-
ing of CBP, pCREB, p300, p/CAF, and MEF-2A but not
Tax to the GAPDH promoter (Figure 3, left panels).
This was not surprising since the amplified region of
GAPDH contained binding sites for these TFs. Al-
though recruitment of some of these factors to the
GAPDH promoter was more efficient in infected cells,
we did not see any increase in GAPDH expression
upon HTLV-1 infection (Additional file 3: Figure S3).
We also observed efficient recruitment of TFs and Tax
to the viral LTR in MT-2 cells (Figure 3A, right panel)
and infected CD4+ cells (Figure 3B, right panel), but
not in uninfected control cells. CD4+CD25+ T cells
were also included in our analysis, as they are the pri-
mary subset of CD4+ T cells targeted by HTLV-1 [67].
These cells showed efficient recruitment of MEF-2A
and other cellular factors to the LTR upon infection
(Figure 3C, right panel). As a control, we enriched cells
for viral core protein p19 and as expected did not detect
recruitment of any factors analyzed to GAPDH or LTR
promoters (Additional file 4: Figure S4). Altogether, these
results confirmed that MEF-2A is recruited to the HTLV-
1 LTR in association with Tax and co-activators of tran-
scription including p300, CBP, and p/CAF.
MEF-2 is upregulated upon HTLV-1 infection and
physically interacts with Tax
Prior to protein-protein interaction studies, we exam-
ined the expression of MEF-2A and other cellular factors
both in cell lines and primary cells without and with
HTLV-1 infection. As shown in Figure 4A, we noticed
an upregulation of the HATs p300, CBP and p/CAF, as
well as TFs, pCREB and MEF-2A upon infection. We
also observed the complex formation of MEF-2A with
Tax and pCREB, confirming a direct interaction with the
Tax/CREB heterodimer complex (Figure 4B). Interest-
ingly, upon infection, the interaction of MEF-2A with
HDAC9 was expectedly diminished since HDAC9 binds
Figure 3 Tax and MEF-2 are recruited to the HTLV-1 LTR. Chromatin immunoprecipitation of Tax protein and transcription factors bound to
cellular and viral promoters during HTLV-1 infection in (A) cell lines, (B) primary CD4+ T cells, and (C) primary CD4+CD25+ T cells was performed
using the ChIP-IT Express kit. Cells were lysed in a dounce homogenizer to obtain sheared chromatin following formaldehyde fixation. The sheared
chromatin was immunoprecipitated at 4°C overnight using 2 μg of antibodies against the Tax protein, indicated cellular factors and controls. The
immunoprecipitated chromatin was then subjected to PCR using primers for HTLV-1 LTR and human GAPDH. Data is presented as average fold change
over control IgG immunoprecipitation, and is representative of three independent experiments.
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Figure 4 MEF-2 physically interacts with Tax. (A) Control (Jurkat), infected (MT-2) cell lines, control primary CD4+ T cells and HTLV-infected primary
CD4+ T cells were lysed, sonicated and protein concentration was determined by Bradford assay. Equal protein quantities were then resolved by
SDS-PAGE and transferred to PVDF membrane. Following a 1 hr block membranes were incubated with antibodies against the transcription factors.
Western blot shows the expression of transcription factors in control and infected cell lines and primary cells. (B) MEF-2 complex formation with Tax
and transcription factors was analyzed using an immunoprecipitation assay. Cells were lysed using an immunoprecipitation lysis buffer and
then incubated with MEF-2 antibody overnight at 4°C as described in Methods. Western immunoblot analysis was performed to confirm
immunoprecipitation. (C) Control and infected cell lines and primary cells were enriched for Tax and immunoblotted to determine complex
formation with MEF-2 and transcription factors. Data is representative of multiple individual experiments.
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transcriptional activity. MEF-2A direct interaction with
Tax was confirmed while enriching for Tax, which
coprecipitated both pCREB and MEF-2A (Figure 4C).
Tax enriched samples contain some levels of HATs but
not HDAC9 suggesting that Tax can directly interact
with co-activators of transcription as shown before [68].
It appeared that anti-Tax nonspecifically pulled down
some MEF-2 in the absence of Tax; however, the band
was greatly increased in the presence of Tax. Neverthe-
less, we performed an alternative experiment to validate
the interaction of these two proteins in C8166 cells,
which contain both Tax and MEF-2 proteins in abun-
dance and demonstrated a specific interaction of these
two proteins (Additional file 5: Figure S5A).
In addition, we transfected 293 T cells (upon detecting
MEF-2 presence in these cells) with the FLAG-Tax ex-
pression plasmid and confirmed the expression of Tax in
the lysate. We then precipitated epitope-tagged Tax with
the anti-FLAG antibody and performed Western blot-
ting with the anti-MEF-2 antibody, which led to the
detection of a specific band in FLAG-Tax transfected
but not mock transfected sample (Additional file 5:
Figure S5B).
MEF-2 co-localizes with Tax
To confirm that MEF-2 interacts with Tax not only in
solution but also within the infected cells, we performed
confocal microscopy using two HTLV-1 transformed cell
lines, MT-2 (Figure 5A) and C8166 (Figure 5B). Tax lo-
calized in the cytoplasm and nucleus in both cell lines.
pCREB as a positive control strongly co-localized with
Tax in the nucleus. Tax and MEF-2A also co-localized
within the nuclear compartment. As a negative control,
a cytoplasmic protein (IRAK1) without any known inter-
action with Tax was used. As expected, this protein did
not co-localize with Tax in either cell type.
Altogether, these results clearly showed a direct inter-
action of MEF-2A with the Tax/CREB heterodimer
complex suggesting that MEF-2 may facilitate the
stabilization of the complex between Tax and CREB on
the HTLV-1 LTR in addition to directly participating in
the transactivation process. This was confirmed by
knocking down MEF-2A in MT-2 cells and testing forthe Tax/CREB recruitment to the LTR by a novel
promoter-binding assay.
HTLV-1 LTR transcriptional activation complexes contain
MEF-2
In order to confirm that HTLV-1 LTR transcriptional
complexes contain MEF-2, we performed a promoter-
binding TF profiling assay. Use of this assay offers the
advantage of analyzing multiple TFs at once as opposed
to electrophoretic mobility shift assay, which enables
characterization of only a single TF at a time. This assay
is based upon the fact that if a TF binds the LTR, then
the binding of that factor with its oligonucleotide is re-
duced due to competition between the probe and LTR.
Of the 50 total TFs, only 19 including MEF-2 showed an
ability to compete for binding to the LTR at significant
levels (Figure 6). Observed binding of CREB validated the
assay, since it is an established factor that interacts with
Tax and facilitates transactivation process [29,69-71].
Some other cellular factors were identified (i.e. AR, Brn-3,
Pbx1, etc.) whose roles remain to be tested in HTLV-1
pathogenesis. Similarly, 31 cellular factors (i.e. ATF2,
CAR, EGR, etc.) did not show significant competitive in-
hibition of LTR binding within MT-2 cells. These observa-
tions were made in the setting of active infection where
both Tax and MEF-2 were readily available to mediate the
process.
Upon inhibition of both MEF-2A (Figure 6A) and Tax
(Figure 6B), almost all TFs (except AR) lost their binding
to LTR and some were present in much higher levels
compared to control (MT-2 cells without any inhibition
and exogenous LTR). Inhibition of Tax or MEF-2 af-
fected each other protein levels (confirmed by Western
and FACS). In both cases, MEF-2 was not present in the
nuclear extract; therefore, a majority of MEF-2 probe
molecules in the assay remained unbound and were
washed off leading to a low signal. While other cellular
factors being freed from the LTR exhibited higher signals
depending upon their relative abundance in the nuclear
extract. Of these factors, nuclear factor of activated T
cells (NFAT) was found to be of great significance.
NFAT, upon activation, translocates into the nucleus and
cooperates with various transcription factors including
MEF-2 to promote their transcriptional activity [62,72].
Figure 5 MEF-2 co-localizes with Tax in the nucleus of HTLV-1 transformed cell lines. MT-2 cells (A) and C8166 cells (B) were cultured
overnight on poly-L-lysine coated glass coverslips. The cells were then fixed, permeabilized and then stained with anti-Tax, anti-MEF-2, anti-CREB
or anti-IRAK1 as indicated. Nuclei were stained with DAPI and cells were subjected to confocal microscopy.
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Figure 6 HTLV-1 LTR transcriptional activation complexes contain MEF-2. Binding of various transcription factors present in the nuclear
extract isolated from MT-2 cells to the HTLV-1 LTR was assessed using the Promoter-Binding Transcription Factor Profiling Array I upon knocking
down MEF-2A (A) and Tax (B) as described in Methods. The nuclear extract was incubated with oligonucleotide probe mix with the HTLV-1 LTR
or a control DNA. The binding of each transcription factor to LTR was indicated by average reduction in chemiluminescence of transcription
factor-specific oligonucleotide probe specific to each factor from triplicate samples.
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only in the absence of Tax (Figure 6B) but also MEF-2
(Figure 6A). The dephosphorylation and activation of
NFAT is mediated by a calcium-dependent serine-
threonine phosphatase, called Calcineurin. Tax has been
shown to activate calcineurin [73-75], and its inhibition
in MT-2 cells resulted in significant reduction in the cal-
cineurin activity (Additional file 6: Figure S6). Thus
physical interaction between NFAT and MEF-2 protein
provides a mechanism for Tax-mediated activation of
MEF-2 via calcineurin signaling. Additional file 7: Table
S1 provides intensity values (raw and average) of all ana-
lyzed TFs in each condition.
MEF-2 directly binds to the HTLV-1 LTR and regulates Tax
activation of the LTR
Results from the competitive promoter assays and CHIP
assays confirmed that MEF-2 is recruited to the HTLV-1
LTR suggesting the presence of a MEF-2 binding site(s)
within the LTR. Therefore, we examined the consensus
site for all MEF-2 isoforms CTA(T/A)4TA(G/A)C within
the LTR and identified two imperfect MEF-2 sites - one
just downstream of repeat III of the Tax-response elem-
ent (TRE) and upstream of the TATA box (Figure 7A,
blue highlight) that matches 7/10 bases of the consensus
site; the other overlaps with the TATA box (Figure 7B,
red highlight), which is highly unlikely to be functional
due to competition with general TFs. To determine if
MEF-2 interacted with the more upstream MEF-2 site in
the HTLV-1 LTR, a double-stranded DNA probe corre-
sponding to this site was generated and used for EMSA
DNA binding assays. EMSA revealed a specific protein/
DNA complex with nuclear extracts from the HTLV-1
transformed cell lines MT-2, MT-4 and C8166, but not
Jurkat cells (Figure 7B). To demonstrate that this protein
complex consisted of MEF-2, competition EMSA assays
were performed with 200–400 fold molar excess of un-
labeled consensus MEF-2 probe or a mutated MEF-2
probe. As seen in Figure 7C, unlabelled consensus MEF-
2, but not the mutant form, effectively competed with
the MEF-2 probe derived from the HTLV-1 LTR for pro-
tein binding. This result strongly supports the idea that
MEF-2 directly binds to the imperfect MEF-2 site in the
HTLV-1 LTR, just upstream of the TATA box. To ascer-
tain the functional significance of this MEF-2 site, the
first three nucleotides were mutated (CTA- > ACG) in
the context of the HTLV-1 LTR luciferase reporter.Luciferase assays were conducted to examine Tax activa-
tion of a wild-type HTLV-1 LTR and the MEF-2 mutated
LTR. As expected, Tax strongly activated the HTLV-1
LTR; however, Tax-induced activation of the MEF-2 mu-
tant LTR was significantly decreased even though Tax
expression was similar (Figure 7D). Together, these re-
sults indicate that MEF-2 directly binds to DNA in the
HTLV-1 LTR and is important for Tax activation of the
LTR.
MEF-2 associated signaling pathways are triggered by
HTLV-1 infection
The transcriptional activity of MEF-2 is regulated by
protein modifications including phosphorylation, acetyl-
ation, sumoylation, etc. In addition, MEF-2 is known to
integrate a number of signaling pathways, including
PI3K/Akt, NF-κB, MAPK, TGF-β and JAK/STAT signal-
ing [33,38,76]. While many of these signaling pathways
are known to be activated by Tax, we obtained a global
perspective on these signaling events upon HTLV-1 in-
fection of CD4 T cells by a DNA-protein array. This type
of interactome profiling of primary CD4 T cells upon
HTLV-1 infection has not been reported yet. In general,
an upregulated transcriptome profile was seen in both
MT-2 and primary infected CD4+ T cells, emphasizing
the highly active and dynamic process of viral infection
(Additional file 8: Figure S7A and B). For analysis, cellu-
lar factors included in the array were grouped according
to their association with relevant signaling pathways in
Table 1 and the fold-change in protein expression of the
key cellular factors from the MEF-2-integrated signaling
cascades is given in Figure 8A. Upon validation of array
data by Western blotting, the phosphorylated form of
MEF-2A as well as of p38, ERK5, Smad2 and Akt were
found to be upregulated upon infection in both MT-2
and primary cells (Figure 8B). Thus, our model (Figure 9)
suggests that Tax-mediated activation of cellular signal-
ing pathways contribute to the phosphorylation and acti-
vation of MEF-2, which is then dissociated from class II
HDACs and interacts with Tax at the viral promoter to
boost Tax-mediated transactivation, viral replication as
well as T-cell transformation. Tax also binds to Smad2/
3/4 to prevent their constitutive binding to transcription
co-activators CBP/p300. This leads to increased avail-
ability of CBP/p300 to bind Tax/pCREB complex bound
to the 5′ LTR region of the provirus. Along with Tax/
pCREB/CBP/p300 complex, recruitment of MEF-2A to
Figure 7 (See legend on next page.)
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Figure 7 Assessment of MEF-2 binding site(s) within the HTLV-1 LTR. (A) HTLV-1 LTR nucleotide sequence with two putative MEF-2 binding
sites shown in blue and red. The HTLV-1 LTR comprises U3 (unique 3′), R (Repeated), and U5 (unique 5′) regions. The U3 region regulates viral
gene expression via three 21 bp repeats known as Tax-responsive element - 1 (TRE - 1), which confers Tax-based trans-activation. These repeats
contain 3 conserved domains labeled A, B and C. The location for ATF/CREB binding and putative MEF-2 binding are illustrated. (B) EMSA was
performed with a probe corresponding to the MEF-2 site in the HTLV-1 LTR using nuclear extracts from Jurkat, MT-2, MT-4 and C8166 cells. (C)
EMSA competition assay was performed using nuclear extracts from MT-2 cells, with increasing amounts of unlabeled consensus MEF-2 specific
probe (200, 300 and 400 fold molar excess respectively) or a mutated MEF-2 specific probe. Oct-1 was used as a loading control. (D) HTLV-1 LTR
luciferase assays in 293 T cells transfected with empty vector (EV) or Flag-Tax using LTR luciferase WT plasmid (LTR Luc WT) or a MEF-2-specific
binding mutant (LTR Luc MEF-2 Mut). Luciferase values are presented as “fold induction” relative to the control (EV). Two-tailed unpaired t-test
was performed with Prism software. Error bars represent the standard deviation of triplicate samples. The level of significance was defined as:
***p < 0.001. Western blots were performed with anti-Flag and anti-β-actin using whole-cell lysates.
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hand, Tax also activates Calcineurin (a calcium-dependent
serine-threonine phosphatase), which dephosphorylates
NFAT. Upon dephosphorylation, NFAT translocates to
the nucleus and is recruited to the HTLV-1 LTR along
with the Tax/pCREB/CBP/p300 complex. NFAT is also re-
cruited to the MEF-2A gene promoter where it binds to
MEF-2A and turns on transcription resulting in upregula-
tion of MEF-2A expression. Interestingly, in Figure 4A we
showed that MEF-2 in its native form was also upregu-
lated upon HTLV-1 infection making more MEF-2 avail-
able for interaction with Tax. This heightened expression
of MEF-2 could be a result of Tax-induced calcineurin ac-
tivity that in turn results in NFAT-mediated MEF-2 tran-
scription via binding to its own promoter.
Discussion
While the precise molecular mechanisms that influence
HTLV-1 clinical latency versus active disease remain
poorly understood, it is well established that Tax is es-
sential for efficient HTLV gene expression [11-13,70,77].
Tax-mediated transcriptional regulation occurs via direct
interaction with the CREB homodimer to form a stable
Tax/CREB complex [21-24,27-29]. Complex binding at
TREs within the viral promoter initiates HAT recruit-
ment to facilitate nucleosome acetylation and disassem-
bly, thus enabling active viral transcription [19,25,26,29].
Previously we showed a differential requirement for chro-
matin remodeling machinery in human T cells with stably
versus transiently integrated viral LTR [69]. Herein, we
provide evidence of recruitment of a novel cellular factor,
MEF-2, to the LTR and its role in viral pathogenesis.
Although, it is considered a transcriptional activator, the
regulatory activity of MEF-2 is determined by its second-
ary interactions. MEF-2 remains constitutively bound to
target gene promoter regions, but is held transcriptionally
silent through associations with class II HDAC complexes
that maintain the chromatin in a condensed, hypoacety-
lated state [35,38,76]. In the unstimulated state, HDAC9
interacts with MEF-2 and represses its activity; whereas
upon activation of intracellular signaling pathways involv-
ing Ca2+/calmodulin-dependent kinase (CaMK) andprotein kinase D, it undergoes CRM1-dependent nuclear
export [38,78,79]. Besides this, other regulatory mecha-
nisms, such as sumoylation [80,81], caspase cleavage
[82,83], ubiquitin-dependent proteosomal degradation
[84,85], and mitochondrial targeting [86], have also been
reported for negative regulation of class IIa HDAC ac-
tivity. In contrast, MEF-2 can also get activated through
direct modification by p38 MAP kinase and ERK5-
mediated phosphorylation [44,49,55-60]. Phosphoryl-
ation of MEF-2A at Thr312 and Thr319 within the
transcription activation domain by p38 enhances MEF-
2A: MEF-2D heterodimer-dependent gene expression
[49]. HTLV-1 Tax has been shown to activate p38 and
other MAP kinases [53,54]. Tax also operates at an-
other level to promote Tax-mediated transcriptional ac-
tivation of the viral LTR. Tax binds the N-terminus of
Smad2, Smad3, and Smad4 proteins, which inhibits
their association with Smad-binding elements and co-
activators CBP/P300 [87]. This causes an increase in
availability of CBP/P300 to bind to Tax leading to in-
creased viral gene expression. Herein, we demonstrated
successful inhibition of MEF-2 and its consequence on
Tax-mediated LTR activation (Figure 1A), viral gene ex-
pression (Figure 1B), viral replication (Figure 1C), and
CD4 T-cell transformation (Figure 2A-B). Physiological
relevance of MEF-2 was also established as ATL pa-
tients expressed more MEF-2 compared to controls
(Figure 2C). MEF-2 expression was inhibited by an
shRNA specific for MEF-2A and its activity was inhib-
ited by the MITR plasmid that encodes HDAC9. The
ubiquitous nature of MEF-2 makes it difficult to
achieve an efficient knockdown in expression; however,
HDAC9 efficiently represses the transcriptional activation
of MEF-2 [35,88-90]. While shRNA was specific for MEF-
2 isoform “A”, HDAC9 is known to repress transcriptional
activity of all MEF-2 isoforms [35,88-90]; however, similar
levels of inhibitions was achieved by both in Figure 1A
suggesting that MEF-2A could be the major player in Tax
activity on HTLV-1 LTR. Upon confirmation of MEF-2
importance in HTLV-1 pathogenesis we investigated the
underlying molecular processes as well as MEF-2 regula-
tion by Tax and cellular factors (Figures 3, 4, 5, 6, 7 and 8).
Table 1 Raw densities of the transcription factors included in the Protein/DNA array analysis, grouped according to
association with general signaling pathways
Raw densities
Signaling pathways Transcription factors Jurkat MT-2 Control CD4 Infected CD4 T cells
Akt signaling AP-(2) 29011 ± 312 36283 ± 2049 126 ± 3 285 ± 2
Brn-3 20098 ± 857 43533 ± 350 0 262 ± 2
GATA 12325 ± 357 34756 ± 1662 0 284 ± 1
NFAT 16264 ± 921 35151 ± 358 103 ± 2 284 ± 1
NF-E1 27661 ± 910 45077 ± 611 120 ± 1 326 ± 3
PAX-5 26980 ± 1038 33945 ± 97 120 ± 1 261 ± 2
Pit-1 11622 ± 386 29345 ± 283 0 296 ± 3
PPAR 13329 ± 467 31100 ± 82 107 ± 2 264 ± 1
PRE 14780 ± 196 30151 ± 417 109 ± 0 263 ± 3
TR 23845 ± 973 3172 ± 231 0 296 ± 3
MAP kinase signaling AP-1(2) 26548 ± 1383 39830 ± 2086 133 ± 8 284 ± 1
AP-1(1) 19105 ± 524 45066 ± 1252 100 ± 1 284 ± 1.6
CDP 14854 ± 434 29735 ± 75 106 ± 2 253 ± 2
CEBP 20286 ± 68 37664 ± 693 115 ± 3 257 ± 2
E2F1 25614 ± 251 47332 ± 149 126 ± 6 323 ± 8
ER 30792 ± 1518 42869 ± 335 127 ± 7 284 ± 4
Ets 17337 ± 489 32485 ± 1058 114 ± 1 265 ± 3
IRF-1 13996 ± 124 26838 ± 30 102 ± 1 241 ± 2
MEF-1(1) 23260 ± 405 47037 ± 954 133 ± 1 287 ± 2
MEF-2(1) 15230 ± 107 28955 ± 492 105 ± 2 244 ± 5
c-Myb 23884 ± 1150 32938 ± 656 118 ± 0 270 ± 2
NF-1 14970 ± 920 28197 ± 45 114 ± 1 258 ± 5
Pbx-1 13464 ± 336 29920 ± 67 109 ± 0 245 ± 4
p53 24993 ± 372 31927 ± 89 120 ± 0 270 ± 2
USF-1 277010 ± 272 34861 ± 171 117 ± 2 285 ± 0
VDR/DR-3 26164 ± 145 32870 ± 246 117 ± 0 281 ± 1
NF-kB signaling HSE 15326 ± 371 30604 ± 440 111 ± 0 263 ± 5
NF-E2 28464 ± 800 39988 ± 2116 117 ± 2 307 ± 4
JAK/STAT signaling GAS/ISRE 12857 ± 427 34972 ± 566 109 ± 4 238 ± 10
HNF-4 19187 ± 108 42759 ± 1490 116 ± 1 281 ± 1
STAT 1 15351 ± 156 32659 ± 157 116 ± 1 294 ± 5
STAT 3 17637 ± 567 33608 ± 142 116 ± 2 0
STAT 4 29321 ± 608 37269 ± 462 126 ± 2 270 ± 0
TGF-β signaling FAST-1 15054 ± 756 33012 ± 477 116 ± 0 294 ± 5
Myc/Max 26136 ± 1301 0 0 0
RAR/DR-5 28178 ± 45 36611 ± 97 117 ± 0 275 ± 2
SBE/Smad 16635 ± 511 30441 ± 626 108 ± 1 248 ± 5
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MEF-2 activity is regulated during HTLV-1 infection. Tax
activates a multitude of cellular signaling pathways, in-
cluding those integrated by MEF-2. To our surprise, previ-
ously published interactome studies for HTLV-1 [91] orTax interactome [68,92], did not identify MEF-2 as a po-
tential player thereby enabling presented studies to be the
first in this line.
MEF-2 has shown to be required for B cell prolifera-
tion and survival after antigen receptor stimulation [93]
Figure 8 (See legend on next page.)
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Figure 8 MEF-2-associated signaling pathways are triggered during HTLV-1 infection. (A) A protein-DNA array was used to determine the activation
of the various eukaryotic transcription factors. Nuclear extracts from control and HTLV-infected primary cells were mixed with biotinylated
DNA binding oligonucleotides for the formation of protein-DNA complexes. These probes were then hybridized to pretreated array membranes and the
bound probe was detected as described in Methods. Densitometric analysis was used to quantify the spots and data was normalized to their respective
controls after background subtraction. Fold change in expression of selected transcription factors from the array data compared to relevant uninfected cells.
Significance was determined using the Student’s t-test (*P≤ 0.05). (B) Cells were lysed and Western blotting was performed to confirm the array data.
Figure 9 Model explaining MEF-2 activity on Tax-mediated transactivation of HTLV-1 LTR. Type II HDACs (HDAC4/5/7/9) bind to MEF-2A
and repress its transcriptional activity. Upon HTLV-1 infection, Tax activates p38 and ERK5, which phosphorylate MEF-2 leading to its dissociation
from the MEF-2A: HDAC repressive complex. On the other hand, Tax also binds to Smad2/3/4 to prevent their constitutive binding to transcription
co-activators CBP/p300. This leads to increased availability of CBP/p300 to bind Tax/pCREB complex bound to the 5′ LTR region of the provirus. Along
with Tax/pCREB/CBP/p300 complex, recruitment of MEF-2A to the 5′ LTR promotes viral gene expression. Tax also activates Calcineurin (a calcium-
dependent serine-threonine phosphatase), which dephosphorylates NFAT. Upon dephosphorylation, NFAT translocates to nucleus and is recruited to
the HTLV-1 5′ LTR along with the Tax/pCREB/CBP/p300 complex. NFAT is also recruited to the MEF-2A gene promoter where it binds to MEF-2A and
turns on transcription resulting in upregulation of MEF-2A expression. HDAC, Histone deacetylase; MEF-2A, Myocyte-specific enhancer factor 2A; ERK5,
Extracellular-signal-regulated kinase 5; Smad, Sma- and Mad-Related Protein; CREB, cAMP response element-binding protein; CBP, CREB-binding protein;
NFAT, Nuclear factor of activated T cells.
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differentiation [94]. MEF-2C deficiency is associated
with defects in the production of B cells, T cells, natural
killer cells and common lymphoid progenitor cells [95].
Tax-mediated recruitment of MEF-2 to the viral pro-
moter may capitalize on these conserved mechanisms to
activate viral transcription. For example, in thymocyte
negative selection, expression of Nur77 is dependent on
MEF-2; while MEF-2 remains constitutively bound to
the promoter, it is held transcriptionally silent by interac-
tions with Cabin1, which recruits the co-repressor mSin3a
in association with class II HDACs [38,40,41,96-100].
However, increases in intracellular calcium levels activate
the mobilization of calcineurin and calmodulin, which dis-
place the Cabin1/mSin3a/HDAC inhibitory complex and
allow p300, p/CAF and CBP binding. MEF-2 is known to
integrate a number of overlapping cellular signaling path-
ways that are also influenced by calcium signaling. This
study and previous ones have shown that Tax activates
Calcineurin, which dephosphorylates NFAT. Upon de-
phosphorylation, NFAT translocates to the nucleus and is
recruited to the HTLV-1 5′ LTR along with the Tax/
pCREB/CBP/p300 complex. NFAT is also recruited to the
MEF-2A gene promoter where it turns on transcription
resulting in upregulation of MEF-2 expression.
Conclusions
Our study provides the first evidence for the involve-
ment of MEF-2 in Tax-mediated LTR activation, viral
replication, and T-cell transformation. The relevance of
this finding is established by the fact that we found an
increased expression of MEF-2 in ATL patients com-
pared to controls. The underlying molecular mecha-
nisms include the direct binding of MEF-2 to DNA
within the HTLV-1 LTR in the context of chromatin and
the MEF-2 dependent co-regulation of transcriptional
complex involving both Tax and CREB. MEF-2 activity
may be regulated by MEF-2 integrated signaling path-
ways that were activated during HTLV-1 infection of pri-
mary CD4+ T cells.
Methods
Cell lines and plasmids
The HTLV-1-transformed cell line C8166 [101], and
HTLV-1 producing cell lines, MT-2 [102] and MT-4 are
described previously [103,104]. Jurkat cells, a human
CD4 T cell line and Human embryonic kidney cells
(HEK 293 T) were purchased from ATCC. Expression
vectors encoding pU3R-Luc (LTR-Luc), pRL-TK (thymi-
dine kinase), pCMV-Tax and Tax M47 have all been de-
scribed previously [105,106]. MEF-2 expression plasmid
32958 (pCGN-MEF2A-HA), and a luciferase reporter plas-
mid 32967 (p3X-Luc-MEF-2A) were purchased through
Addgene (Cambridge, MA). The control scrambled andMEF-2A shRNA (shMEF-2) plasmids were purchased
through Sigma-Aldrich (St. Louis, MO). The plasmid DNA
encoding the MEF-2 interacting transcriptional repressor
(MITR/HDAC9) was purchased through the Dana-Farber/
Harvard Cancer Center DNA Resource Core (PlasmID).
LTR Luc MEF-2 mutant was generated using the Quik-
Change® Site-directed mutagenesis kit (Agilent Technologies)
with the following primers: forward/reverse 5′TGGCT
GAATAAAACGACAGGAGTCTAT3′/5′ATAGACTCCT
GTCGTTTTATTCAGC′.
Transfections and luciferase assays
Jurkat cells (2 × 105/well) were plated in 12 well plates
and transfection was performed using Lipofectamine
LTX as per manufacturer’s recommendation (Life Tech-
nologies, Grand Island, NY) using 1 μg pU3R-luc, 0.5 μg
pCMV-Tax, and/or 2 μg MEF-2A, 1 μg shMEF-2A or
1 μg pHDAC9 plasmids. Where required, HEK 293 T
cells were transfected with the indicated plasmids using
GenJet according to the manufacturer’s instructions
(SignaGen). In either case, cells were lysed 24 hr post-
transfection using passive lysis buffer and luciferase ac-
tivity was analyzed by the dual Luciferase Assay System
(Promega, Madison, WI). Firefly luciferase values were
normalized based on the Renilla luciferase internal
control values. Each assay was performed in triplicate
and repeated at least three times. A general estimate of
transfection efficiency was obtained using the pMax-
GFP (Lonza) plasmid (Life Technologies). Also, the
shRNA-mediated inhibition of MEF-2A expression was
confirmed in total RNA (Qiagen RNeasy kit) by RT-
PCR with primers for MEF-2A forward/reverse 5′
TCTCCACCTCAAACCACATTAC3′/5′CGTCCATCC
TCATTCG CTTA3′, and GAPDH 5′GATTCCACCC
ATGGCAAATTC3′/5′GTCATGAGTCCTTCCA CGA
TAC3′. Tax expression upon pCMV-Tax transfection
was also confirmed using Tax primers 5′CATGTACCT
CTACCAGCTTT3′/5′GGGCAGGGCCCGGAAATCAT3′.
In addition, extracellular LDH (Lactate Dehydrogenase)
Cytotoxicity Assay (Pierce Thermo Scientific, Rockford,
IL) to assess cellular viability post-transfection.
Effect of MEF-2 inhibition on Tax expression, and HTLV-1
replication
Either scrambled or shMEF-2A plasmid (1 μg) was
transfected into 107 MT-2 cells using program U-014 on
Amaxa Nucleofector II device (Lonza, Switzerland) fol-
lowing manufacturer’s recommendations. Cells were har-
vested at 24 and 48 hr and lysed in M-PER protein
extraction reagent (Pierce). Lysates were sonicated and
analyzed by Western blotting for MEF-2A (Cell Signal-
ing Technologies, Danvers, MA), Tax (LT-4, 1:2000 dilu-
tion, provided by Dr. Yuetsu Tanaka, Japan) and β-actin
(Millipore). Anti-MEF-2A Ab used here does not cross-
Jain et al. Retrovirology  (2015) 12:23 Page 19 of 24react with related family members. To analyze effects of
shMEF-2A on virus production, transfected MT-2 cells
were washed at 48 hr and incubated in fresh medium for
another 24–36 hr. Thereafter, supernatants were assessed
for HTLV-1 core protein levels (pg/ml) by the p19-specific
ELISA (ZeptoMetrix, Buffalo, NY).
Further, the transcriptional repressor MITR/HDAC9
was used to assess the influence of inhibiting MEF-2 activ-
ity on HTLV-1 replication. Briefly, 1 μg of this plasmid
was transfected into 107 MT-2 cells using Lipofectamine
as above. Transfected cells were harvested every 24 hr
over a 72 hr period and transcript analysis was performed
by SYBR Green Cells-to-Ct procedure (Life Technologies)
using the primer sets for Tax 5′CGTGTTTGGAGAC
TGTGTAC3′/5′CTG TTTCGCGGAAATGTTTT3′, p19
5′CACCCCTTTCCCTTTCATTCACGA3′/5′CCGGCCGG
GGTATCCTTTT3′; and GAPDH 5′CAATGACCCCTTC
ATTGACC3′/5′TTGATTTTGGAGGGATCTGG3′. Quan-
titative PCR was performed using Applied Biosystems
7500 System, and fold-change in expression was calcu-
lated by 2-ΔΔCT method [107].
T-cell Transformation assay and Propidium Iodide (PI)
staining
Peripheral blood mononuclear cells (PBMCs) were iso-
lated using Ficoll-Paque (Amersham, Uppsala, Sweden)
and stimulated with phytohemagglutinin (PHA 2 mg/
ml) for 3 days as described [64]. Cells were transduced
with lentivirus expressing either scrambled or shMEF-
2A (Sigma) by spinoculation (1500 g for 3 hr) and incu-
bated for 6 hr. Transduced cells were co-cultured with
lethally irradiated (60 Gy) MT-2 cells at 1:5 ratio in pres-
ence of recombinant IL-2 (20 IU/ml, R&D Systems).
After 3 weeks, puromycin (1 mg/ml) was added to media
to select transduced cells and viable cells were counted
at 3, 5 and 6 weeks.
For the cell cycle progression study, MT-2 and Jurkat
cells were transfected with control or shMEF-2A plasmid
as above and fixed in 70% ethanol overnight at −20°C.
Cells were washed, stained (20 min, RT) with 300 μl of
hypertonic buffer (PI-25 μg/ml, RNAase 40 μg/ml, sodium
citrate-0.1%, and Triton-100 × −0.03%), and analyzed by
flow cytometry. The resulting DNA distributions were an-
alyzed by the Cell Proliferation tool in the software Flowjo
(Tree Star Inc., USA), for the proportions of cells in G0-
G1, S, and G2-M phases of the cell cycle.
MEF-2 mRNA levels in clinical samples
PBMCs from three seronegative controls, asymptomatic
carries and ATL patients were used from a Jamaican co-
hort, which was recently utilized in our studies [108,109].
These samples were obtained from National Cancer Insti-
tute, and processed under institutional review board
guidelines. Total RNA from each sample was transcribedto cDNA and amplified in a standard real-time PCR reac-
tion as described above using primers for MEF-2A
(5ACCGAGAGGATAATTCAGTCCTG3′/5ACATCCGC
GCAC GGATC3′), and GAPDH. RNA from Jurkat T cells
was also amplified as control.
Primary cells and infection
PBMCs were obtained as described above and CD4+
T cells were isolated by a negative selection kit (Stem-
Cell Technologies, Canada). Where indicated, labeled
CD4+CD25+ T cells were isolated by positive selection
for CD25+ from enriched CD4+ T cells. In each case, pur-
ity of cells was confirmed by flow cytometry. For infection,
target cells (5 × 106) were exposed to 125 ng/ml of HTLV-
1 virus (Advanced Biotechnologies) for 72 hr. This prepar-
ation includes 4.62 × 1011 virus particles/ml in 1.2 mg/ml
of total protein, which is equivalent to 0.5 mg/ml of
HTLV-I Gag protein based on the p19 ELISA (ZeptoMe-
trix). We have successfully used this virus preparation in
previous studies for different cell types [65,66]. Infection
was verified by syncytia formation, Western blot analysis
for Tax expression and intracellular Tax analysis by flow
cytometry as per [65].
Chromatin immunoprecipitation (ChIP) assay
Chromatin immunoprecipitation was performed using
the ChIP-IT Express procedure as described by the
manufacturer (Active Motif, Carlsbad, CA). Briefly 107
cells were fixed with formaldehyde solution for 10 min
and then washed with PBS; fixation was stopped using
glycine-stop fix solution. The cells were lysed in a
dounce homogenizer and sonicated for 10 pulses of
2 min each to obtain sheared DNA. The sheared chro-
matin was immunoprecipitated overnight at 4°C with
2 μg of the following antibodies: mouse monoclonal IgG
(Santa Cruz Biotechnology, Santa Cruz, CA), CBP
(Abcam, Cambridge, MA), pCREB (Santa Cruz Biotech-
nology), p300 (Abcam), p/CAF (Abcam), MEF-2 (Santa
Cruz Biotechnology), Tax (LT-4) and p19 (ZeptoMetrix).
Immunoprecipitated chromatin was eluted and then sub-
jected to PCR using the following primer sets: LTR for-
ward/reverse 5′GCCTCTCCTCCTACTTTTATGATG3′/
5′ACCTTGGTCTCGTTTTCACT3′, and human GAPDH
as above. PCR was performed in triplicate, and at least
three independent samples were examined. Input DNA
was used to draw a standard curve and to calculate % input
as per the manufacturer’s instructions (Active Motif).
Co-immunoprecipitation assay
First, protein levels of MEF-2A and other cellular factors
were assessed in Jurkat, MT-2, control and HTLV-
infected primary CD4+ T cells by Western blotting.
Equal protein quantities from each sample were resolved
by SDS-PAGE and transferred to a PVDF membrane.
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temperature with Odyssey blocking buffer (Li-Cor Bio-
sciences) and then incubated with antibodies against
β-actin (Millipore), p300, p/CAF, and CBP (Abcam),
pCREB, and MEF-2A (SC-313, Santa Cruz), HDAC9
(Thermo-Pierce) for 1 hr. Membranes were incubated
with IRDye-conjugated secondary antibodies and signals
were detected using Odyssey Infrared Imager (Li-Cor).
For Co-IP, cells were suspended in ice-cold lysis buffer
[Tris–HCl pH 7.4 (25 mM), NaCl (150 mM), NP-40 (1%),
EDTA (1 mM), glycerol (5%)] and sonicated. The super-
natant was pre-cleared with protein A/G magnetic beads
and immunoprecipitation with 2 μg of MEF-2A (Santa
Cruz) or Tax (LT-4) antibody followed by Western blot-
ting with same set of antibodies as above.
Confocal microscopy
C8166 and MT-2 cells were cultured overnight on glass
coverslips coated with poly-L-lysine. Cells were fixed
with 1% paraformaldehyde and permeabilized with 0.2%
Triton X-100. Fixed cells were incubated with Super-
Block buffer (Thermo Scientific) followed by staining
with a Tax hybridoma (AIDS Research and Reference
Program), and either anti-MEF-2A (Santa Cruz), anti-
CREB (48H2; Cell Signaling), or anti-IRAK1 (D51G7;
Cell Signaling) rabbit antibodies. Cover slips were incu-
bated with Alexa Fluor 555-conjugated donkey anti-mouse
IgG, Alexa Fluor 488-conjugated donkey anti-rabbit IgG
(Life Technologies) and DAPI. Images were obtained using
a Nikon C1si confocal microscope.
Effects of MEF-2A inhibition on transcriptional factors
recruitment to the LTR
The ability of MEF-2 and other cellular TFs to physically
interact with the HTLV-1 LTR was investigated using a
Promoter-Binding TF Profiling Array (Signosis, Sunny-
vale, CA), in the absence or presence of shMEF-2A, as
above. This is a competition assay in which nuclear ex-
tract is incubated with 48 different Biotin-labeled oligo-
nucleotide probes each having affinity to a single TF.
After incubation, TF-bound complexes are eluted, dena-
tured and hybridized in a 96-well plate where each well
has a complementary DNA of a specific probe to capture
it. After capture, oligos are detected using streptavidin-
HRP and a chemiluminescent substrate. Assay was per-
formed as recommended by the manufacturer (Signosis).
Briefly, nuclear extract was isolated from 106 MT-2 cells
and the protein content was estimated by Bradford
assay. The reaction mixture was prepared using 15 μl TF
binding buffer, 3 μl probe, 10 μg nuclear extract and 5 μl
of HTLV-1 LTR or a control DNA, and incubated at
room temperature for 30 min to allow formation of the
TF-DNA complex. Unbound probes were separated
from the complex, while bound probes were eluted andthen hybridized to the plate and incubated overnight at
42°C. Bound probe was detected using HRP-streptavidin
conjugate incubated with the chemiluminiscent sub-
strate. Chemiluminiscence was measured using Top-
Count NXT luminescence counter (PerkinElmer).
This assay was also performed by knocking down Tax in
MT-2 cells by the siRNA approach (Sense strand: 5′
rGrGrC rCrUrU rArUrU rUrGrG rArCrA rUrUrU
rAdTdT 3′; Antisense strand: 5′ rUrArA rArUrG rUrCrC
rArArA rUrArA rGrGrC rCdTdT 3′, IDT) using Lipofecta-
mine RNAiMAX transfection reagent. (Life Technologies).
Both control and siTax-transfected cells were subjected to
the promoter binding assay as well as a Calcineurin Cellular
Activity Assay (Enzo Life Sciences), for which 5 μg of total
protein was incubated with the RII phosphopeptide (a cal-
cineurin substrate) for 30 min. Following incubation, free-
phosphate released was detected colorimetrically (OD at
620 nm) after adding BIOMOL GREEN™ reagent (based on
the classic Malachite green assay). Each condition was per-
formed in duplicate and the human recombinant calcine-
urin was included as a positive control.
Electrophoretic mobility shift assay (EMSA)
Small-scale nuclear extracts were prepared from cells as
described previously [110]. The following sequences
were used to generate double-stranded oligonucleotides
for EMSA: MEF-2 site from HTLV-1 LTR: 5′GAAT
AAACTAACAGGAGTCT3′ (biotinylated at 5′ end),
MEF-2 consensus site from Glut4 promoter [111]: 5′
GGGAGCTAAAAATAGCAG3′, MEF-2 consensus mu-
tant: 5′GGGAGACGAAAACCGCAG3′ and Oct-1: 5′
TGTCGAATGCAAATCACTAGAA3′ (biotinylated at 5′
end). Nonradioactive EMSA was performed using Light-
Shift Chemiluminescent EMSA Kit (Thermo Scientific)
according to the manufacturer’s instructions. Western
blotting was performed essentially as described above.
Whole-cell lysates were resolved by SDS-PAGE, trans-
ferred to nitrocellulose membranes, blocked in 5% milk,
incubated with the indicated primary and secondary anti-
bodies, and detected using Western Lightning enhanced
chemiluminescence reagent (Perkin Elmer). Anti-FLAG
M2 was purchased from Sigma. Anti-β-actin (AC15) was
from Abcam.
Protein/DNA array to profile MEF-2 integrating signaling
pathways upon HTLV-1 infection of primary CD4+ T cells
The activation status of various cellular factors was
assessed by utilizing a Protein-DNA Array I (Panomics)
exactly as previously published [69]. Briefly, nuclear ex-
tract was isolated from 106 cells and mixed with bio-
tinylated probes to allow the formation of protein-DNA
complexes. Labeled probes were eluted from free probes,
hybridized to the pretreated array membranes and
scanned using the FluorChem Imager (Alpha Innotech).
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to their respective controls after background subtraction.
The key identified factors from arrays were verified by
Western blotting for phosphorylated p38 MAPK (Life
Technologies), phospho-ERK5, phospho-Smad2, phospho-
Akt, and phophoMEF-2A (Cell Signaling).Additional files
Additional file 1: Figure S1. (A) Transfection efficiency of Jurkat cells
determined with plasmid pMax-GFP (Lonza) transfected with Lipofectamine
LTX in triplicate as described in Methods. Transfected cells were collected
24 hr post-transfection and analyzed by flow cytometry. Number represents
the transfection efficiency in as percent of GFP-positive cells. (B) Inhibition of
MEF-2 mRNA expression by shRNA was determined by RT-PCR. RNA isolated
from transfected Jurkat cells was converted to cDNA and then amplified
using MEF-2A and Tax primers described in Methods. The PCR product was
then run using a DNA gel and presence of MEF-2A and Tax was confirmed.
(C) LDH cytotoxicity assay was performed on transfected cells to measure
extracellular LDH in culture media. Spectrophotmetric measurement of
a red formazan product was used to confirm that transfection did not
affect cellular viability. (D) HTLV-1 LTR luciferase assays in 293 T cells
transfected with empty vector (Mock) or LTR luciferase plasmid (LTR Luc)
without or with plasmids for Tax, shMEF-2A, HDAC9, and MEF-2A. Luciferase
values are presented as “fold induction” relative to the control (EV).
Two-tailed unpaired t-test was performed with Prism software. Error
bars represent the standard deviation of triplicate samples. The level of
significance was defined as *p < 0.05, **p < 0.01. NS = not significant.
Additional file 2: Figure S2. The infection of primary CD4+ T cells and
cell lines was verified by confirmation of Tax expression. Tax expression
was confirmed in cell lines and primary cells using (A) Flow cytometry,
and (B) Western Blot. Tax mAb (clone LT-4) was used for both flow
cytometry and Western blot. For flow cytometry, allophycocyanin (APC)
was conjugated on Tax mAb.
Additional file 3: Figure S3. HTLV-1 infection does not change GAPDH
expression. Amplification plots are shown following qPCR analysis for
GAPDH expression in cell lines and primary cells.
Additional file 4: Figure S4. Core protein p19 is not promoter bound
during HTLV-1 infection. Quantitative PCR amplification plots following
ChIP analysis show that the viral core protein is not recruited to cellular
or viral promoters.
Additional file 5: Figure S5. Validation of MEF-2 interaction with Tax in
the alternate cell systems. (A) Immunoblotting was performed after IgG
control or Tax immunoprecipitation with the indicated antibodies using
whole cell lysates derived from C8166 cells. This data confirms that Tax
interacts with MEF2 in C8166 cells. (B) Mock or FLAG-Tax expression
plasmid was transfected in 293 T cells for 36 hr. Expression of Tax was
confirmed in the lysate and it was precipitated using an anti-FLAG
antibody followed by immunoblotting with the anti-MEF-2 antibody.
Additional file 6: Figure S6. Inhibition of Tax impacts calcineurin
activity in MT-2 cells. One million MT-2 cells were either mock transfected
(Control) or transfected with siRNA against Tax using Lipofectamine
RNAiMAX Transfection Reagent (Life Technologies) according to manufacturer’s
protocol. After 72 hr, cell lysate was prepared using M-PER (Pierce) and
then used to measure calcineurin activity using Calcineurin Cellular
Activity Assay kit (Enzo Life Sciences). Briefly, 5 μg total protein (from
control as well as siTax transfected cells) was incubated with the RII
phosphopeptide (a calcineurin substrate) for 30 min. Following incubation,
free-phosphate released was detected colorimetrically (OD at 620 nm) after
adding BIOMOL GREEN™ reagent (based on classic Malachite green assay).
Human recombinant calcineurin was included as a positive control. Two
replicates were used and p-value (0.047) was calculated using Student’s
t-test (One-tailed).
Additional file 7: Table S1. Raw and average intensities of analyzed
cellular factors in the promoter binding assay performed with MT-2 cells.Additional file 8: Figure S7. The transcriptome is upregulated and
multiple signaling pathways are activated upon HTLV-1 infection. Schematic
representation of Promoter-Binding Transcription Factor Profiling Assay
(Signosis) (A). Protein-DNA Array plate hybridized with labeled probes
against selected transcription factors each representing a canonical
signaling pathway. Chemiluminescent images collected using the
FluorChem™ Imager (Alpha Innotech) reveal changes in protein binding
activities of the transcription factors indicating activation of multiple
signaling pathways upon HTLV-1 infection (B).
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